Fayez Sarofim & Co
NAUT icon

Fayez Sarofim & Co’s Nautilus Biotechnolgy NAUT Stock Holding History

Fayez Sarofim & Co’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.2K Hold
45,000
– – ﹤0.01% 300
2026
Q1 		$175K Hold
45,000
– – ﹤0.01% 293
2025
Q4 		$87.8K Hold
45,000
– – ﹤0.01% 297
2025
Q3 		$38K Hold
45,000
– – ﹤0.01% 305
2025
Q2 		$32.6K Hold
45,000
– – ﹤0.01% 308
2025
Q1 		$38.7K Buy
+45,000
New +$66.9K ﹤0.01% 310

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Fayez Sarofim & Co's NAUT Position: Q2 2026 in Review

Fayez Sarofim & Co held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 45,000 shares worth $84.2K. The position accounts for ﹤0.01% of the portfolio, ranked #300.

Fayez Sarofim & Co first reported a position in NAUT in Q1 2025 and has held it in 6 quarters since. The position peaked at $175K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Fayez Sarofim & Co held 45,000 shares of Nautilus Biotechnolgy worth $84.2K as of Q2 2026.
  • Fayez Sarofim & Co left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up ﹤0.01% of Fayez Sarofim & Co's portfolio in Q2 2026, its #300 holding.
  • Fayez Sarofim & Co first reported a position in Nautilus Biotechnolgy in Q1 2025 and has held it in 6 quarters since.
  • Fayez Sarofim & Co's Nautilus Biotechnolgy position peaked at $175K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Fayez Sarofim & Co's 13F filing for Q2 2026, filed 17 Aug 2026.